{"schema_version":"secwatch.filing_event.v1","accession":"0000719135-22-000088","form_type":"8-K","ticker":"APYX","cik":"0000719135","company_name":"Apyx Medical Corp","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.345971+00:00","generated_at":"2026-06-22T00:15:13.054646+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Apyx Medical Q3 revenue down 23% YoY; cuts full-year 2022 guidance","bullets":["Total revenue $9.1M (-23% YoY); Advanced Energy revenue $7.1M (-31% YoY).","Net loss $5.8M ($0.17/share) vs $4.2M loss in Q3 2021; Adjusted EBITDA loss $3.9M.","Full-year 2022 revenue guidance cut to $44.8M-$47.9M from prior $51.0M-$56.4M.","Company cites continued disruption from March FDA Safety Communication as primary headwind.","OEM revenue grew 34% to $2.0M, partially offsetting Advanced Energy decline."],"urls":{"canonical":"https://secwatch.observer/filing/0000719135-22-000088","json":"https://secwatch.observer/filing/0000719135-22-000088.json","markdown":"https://secwatch.observer/filing/0000719135-22-000088.md","text":"https://secwatch.observer/filing/0000719135-22-000088.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/719135/000071913522000088/0000719135-22-000088-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/719135/000071913522000088/apyx-20221110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T00:15:13.054646+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d9ea1b026920abb9ff868587c6e6a638dbc53a95","claim":"Apyx Medical Corp reported third quarter ended September 30, 2022 results: revenue $9.1 million, net income Net loss attributable to stockholders of $5.8 million. Guidance reaffirmed.","evidence_excerpt":"third quarter ended September 30, 2022, and updated financial expectations for the full year ending December 31, 2022. Third Quarter 2022 Financial Summary : • Total revenue of $9.1 million, down 23% year-over-year. ◦ Advanced Energy revenue of $7.1 million, down 31% year-over-year. ◦ OEM revenue of $2.0 million, up 34% year-over-year. • Net loss attributable to","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/719135/000071913522000088/0000719135-22-000088-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$9.1 million"},{"label":"Net income","value":"Net loss attributable to stockholders of $5.8 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}